Abbvie Inc ABBV:NYSE

Earnings Announcement Next Earnings date is expected on 02/02/2022
Last Price$136.54Cboe Real-Time Last Sale as of 3:35PM ET 1/27/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+2.31(1.72%)
Bid (Size)$136.54 (153)
Ask (Size)$136.59 (102)
Day Low / High$135.50 - 138.30
Volume7.0 M
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 01/27/2022

 

Abbvie Inc ( NYSE )

Price: $136.54
Change: +2.31 (1.72%)
Volume: 7.0 M
3:35PM ET 1/27/2022
 
 

Eli Lilly and Co ( NYSE )

Price: $236.67
Change: -1.19 (0.50%)
Volume: 1.5 M
3:35PM ET 1/27/2022
 
 

Merck & Co Inc ( NYSE )

Price: $80.94
Change: +1.80 (2.27%)
Volume: 12.6 M
3:35PM ET 1/27/2022
 
 

Pfizer Inc ( NYSE )

Price: $53.61
Change: +1.00 (1.90%)
Volume: 26.2 M
3:35PM ET 1/27/2022
 
 

Bristol-Myers Squibb Co ( NYSE )

Price: $64.02
Change: +1.78 (2.86%)
Volume: 12.4 M
3:35PM ET 1/27/2022
 

Read more news Recent News

Berenberg Bank Adjusts AbbVie's Price Target to $115 From $105, Maintains Hold Rating
7:34AM ET 1/25/2022 MT Newswires

AbbVie (ABBV) has an average rating of outperform and price targets ranging from $105 to $172, according to analysts polled by Capital IQ. (MT Newswires...

Morgan Stanley Adjusts AbbVie's Price Target to $142 from $124, Keeps Overweight Rating
11:08AM ET 1/24/2022 MT Newswires

AbbVie (ABBV) has an average rating of outperform and price targets ranging from $105 to $172, according to analysts polled by Capital IQ. (MT Newswires...

AbbVie Receives FDA Second Indication Approval for Skyrizi to Treat Adults with Active Psoriatic Arthritis
4:40PM ET 1/21/2022 MT Newswires

AbbVie (ABBV) said Friday that the US FDA has approved Skyrizi (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis. According...

Barclays Adjusts AbbVie's Price Target to $133 from $118, Keeps Equalweight Rating
12:20PM ET 1/20/2022 MT Newswires

AbbVie (ABBV) has an average rating of outperform and price targets ranging from $105 to $172, according to analysts polled by Capital IQ. (MT Newswires...

View all Commentary and Analysis

The Zacks Analyst Blog Highlights: AbbVie, Edwards Lifesciences and Johnson Controls International
1:59PM ET 1/27/2022 Zacks

AbbVie, Edwards Lifesciences and Johnson Controls International are included in this analyst blog.

2 Stocks to Buy During Market Turbulence Before Earnings
12:25PM ET 1/27/2022 Zacks

Diving into two strong stocks that also pay a dividend that investors might want to consider buying...

The Retiree's Dividend Portfolio - Jane's December Update: Celebrating 15% Year-Over-Year Dividend Growth
7:08AM ET 1/27/2022 Seeking Alpha

Top Analyst Reports for AbbVie, Edwards Lifesciences & Johnson Controls
6:43PM ET 1/26/2022 Zacks

Today's Research Daily features new research reports on 12 major stocks, including AbbVie Inc....

Company Profile

Business DescriptionAbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's disease, metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL. View company web site for more details
Address1 North Waukegan Road
North Chicago, Illinois 60064-6400
Phone+1.847.932.7900
Number of Employees30,000
Recent SEC Filing01/05/20224
Chairman & Chief Executive OfficerRichard A. Gonzalez
Vice Chairman-Management Board & PresidentMichael E. Severino
Executive Vice President-OperationsAzita Saleki-Gerhardt
CFO, Vice Chairman-Finance & Commercial OperationsRobert A. Michael

Company Highlights

Price Open$135.50
Previous Close$134.23
52 Week Range$101.81 - 138.30
Market Capitalization$241.3 B
Shares Outstanding1.8 B
SectorHealth Technology
IndustryPharmaceuticals: Major
Current Dividend / Yield$1.41 / 4.20%
Dividend Ex-Date01/13/2022
Dividend Pay-Date02/15/2022
Dividend Yield 5 Year Average4.12%
Next Earnings Announcement02/02/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings31.42
Earnings per Share$7.46
Beta vs. S&P 500N/A
Revenue$32.8 B
Net Profit Margin13.51%
Return on Equity56.37%

Analyst Ratings as of 01/17/2022

Buy
15
Overweight
4
Hold
6
Underweight
1
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset